151 related articles for article (PubMed ID: 37964473)
1. Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
Heini AD; Bacher U; Pabst T
Br J Haematol; 2024 Feb; 204(2):389-390. PubMed ID: 37964473
[TBL] [Abstract][Full Text] [Related]
2. UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D; Polerà N; Belmonte B; Conforti F; Signorelli S; Gulino A; Staropoli N; Tuccillo FM; Bonelli P; Juli G; Grillone K; Ascrizzi S; Cirillo M; Migale L; Ballerini A; Pelizon C; Di Martino MT; Tagliaferri P; Riillo C; Tassone P
Br J Haematol; 2024 Feb; 204(2):555-560. PubMed ID: 37963444
[TBL] [Abstract][Full Text] [Related]
3. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
5. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
[TBL] [Abstract][Full Text] [Related]
6. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
[TBL] [Abstract][Full Text] [Related]
7. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
Atallah-Yunes SA; Robertson MJ; Davé UP; Ghione P; Perna F
Front Immunol; 2022; 13():901365. PubMed ID: 35720352
[TBL] [Abstract][Full Text] [Related]
8. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
9. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
10. Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape.
Su X; Sun T; Li M; Xia Y; Li M; Wang D; Lu F; Ye J; Ji C
J Transl Med; 2022 Aug; 20(1):378. PubMed ID: 35986288
[TBL] [Abstract][Full Text] [Related]
11. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
12. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Apollonio B; Spada F; Petrov N; Cozzetto D; Papazoglou D; Jarvis P; Kannambath S; Terranova-Barberio M; Amini RM; Enblad G; Graham C; Benjamin R; Phillips E; Ellis R; Nuamah R; Saqi M; Calado DP; Rosenquist R; Sutton LA; Salisbury J; Zacharioudakis G; Vardi A; Hagner PR; Gandhi AK; Bacac M; Claus C; Umana P; Jarrett RF; Klein C; Deutsch A; Ramsay AG
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37219943
[TBL] [Abstract][Full Text] [Related]
13. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Lawrie C; Moir D; Hatton C; Banham AH; Pulford K
Br J Haematol; 2009 Aug; 146(4):396-407. PubMed ID: 19552722
[TBL] [Abstract][Full Text] [Related]
14. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
16. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Caballero AC; Escribà-Garcia L; Alvarez-Fernández C; Briones J
Front Immunol; 2022; 13():904497. PubMed ID: 35874685
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
18. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
19. A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Riillo C; Caracciolo D; Grillone K; Polerà N; Tuccillo FM; Bonelli P; Juli G; Ascrizzi S; Scionti F; Arbitrio M; Lopreiato M; Siciliano MA; Sestito S; Talarico G; Galea E; Galati MC; Pensabene L; Loprete G; Rossi M; Ballerini A; Gentile M; Britti D; Di Martino MT; Tagliaferri P; Tassone P
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740552
[TBL] [Abstract][Full Text] [Related]
20. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
